Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the mRNA-1647 cytomegalovirus vaccine in healthy adults was terminated; this update reports the study status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• mRNA-1647 (Cytomegalovirus vaccine (mRNA-1647))

Snippet

Sponsor: ModernaTX, Inc. | Conditions: Cytomegalovirus Infection | Phase 3 | Status: TERMINATED